Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the safety of a novel recombinant human papillomavirus bivalent ( types 16 and 18 ) vaccine ( Yeast ) with different dose in healthy females between 9-45 years of age at enrollment.

Official Title
-----------------
A Blind, Randomized and Placebo-controlled Clinical Trial With Recombinant HumanPapillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Health Women-Phase I

Conditions
-----------------
Human Papillomavirus

Intervention / Treatment
-----------------
* Biological: HPV 16/18 vaccine, 0,5ml
* Biological: Placebo control, 0.5ml
* Biological: HPV 16/18 vaccine, 1.0ml
* Biological: Placebo control, 1.0ml


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy female between, and including, 9 and 45 years of age at the time of the first vaccination Provide legal identification for for the sake of recruitment. Be able to understand and sign informed consent prior to enrollment (For subjects below the legal age of consent, informed consent must be signed by parent(s)/legal guardian(s) in addition). Subject must be not pregnant at the enrollment and agree to using adequate contraceptive precautions within 7 months. Exclusion Criteria: History of cervical cancer History of severe allergic reaction requiring medical intervention (such as oral and throat swelling, difficulty breathing, hypotension or shock) History of allergic to vaccine, or to any ingredient of vaccine. History of epilepsy, seizures or convulsions, or family history of mental illness Subjects are immunocompromised or have been diagnosed as suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation (JRA), inflammatory bowel disease or other autoimmune diseases, administration of immunosuppressants with six months prior to the first vaccine dose. History of asthma, thyroidectomy, angioneurotic edema, diabetes or malignant Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency, coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder Acute disease or chronic disease acute exacerbation 7 days prior to vaccination Administration of immunoglobulins and/or any blood products within 3 months, or administration of any live attenuated vaccine within 28 days, or administration of any subunit or inactivated vaccines within 14 days. Fever or axillary temperature> 37.0 °C before vaccination During menstrual period, breastfeeding, pregnancy(pregnancy test positive), or planned pregnant within 7 month History of hypertension, physical examination systolic blood pressure> 150mmHg and/or diastolic blood pressure> 100mmHg Abnormal laboratory tests parameters Any clinical significant disease or findings during study screening that, in the opinion of the Investigator may interfere with the study

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Adult Group 1, HPV vaccine 0.5ml<br>20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines. | Biological: HPV 16/18 vaccine, 0,5ml<br>* Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule<br>|
| Placebo Comparator: Adult Group 1, Placebo 0.5ml<br>20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate. | Biological: Placebo control, 0.5ml<br>* Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.<br>|
| Experimental: Adult Group 2, HPV vaccine 1.0ml<br>20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines. | Biological: HPV 16/18 vaccine, 1.0ml<br>* Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule<br>|
| Placebo Comparator: Adult Group 2, Placebo 1.0ml<br>20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate. | Biological: Placebo control, 1.0ml<br>* Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.<br>|
| Experimental: Children Group 1, HPV vaccine 0.5ml<br>20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines. | Biological: HPV 16/18 vaccine, 0,5ml<br>* Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule<br>|
| Placebo Comparator: Children Group 1, Placebo 0.5ml<br>20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate. | Biological: Placebo control, 0.5ml<br>* Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.<br>|
| Experimental: Children Group 2, HPV vaccine 1.0ml<br>20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines. | Biological: HPV 16/18 vaccine, 1.0ml<br>* Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule<br>|
| Placebo Comparator: Children Group 2, Placebo 1.0ml<br>20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate. | Biological: Placebo control, 1.0ml<br>* Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence, intensity and relationship to vaccination of any solicited local or systemic reactions. |  | 7 days after each vaccine dose | 
| Occurrence, intensity and relationship to vaccination of any unsolicited symptom. |  | 30 days after finish vaccinations | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neutralizing antibody responses of HPV 16/18 after each vaccine dose. |  | 30 days after finish vaccinations | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Human papillomavirus, vaccine, cervical infection, cervical cancer